News

Proteomics inks kidney disease test deal in Mid-East – The West Australian

The Perth-headquartered company said on Thursday that it has inked a licencing deal with Zotal Ltd giving the Tel Aviv-based medical distributor the right to sell the easy-to-use immunoassay version of PromarkerD, known as PromarkerD (IA), to clinical laboratories across Israel.

A recent international multi-centre clinical study into Proteomics’ predictive test found that patients identified by PromarkerD were 13.5 times more likely to develop CKD during a 4-year period.

Article: Proteomics inks kidney disease test deal in Mid-East

Subscribe
  • This field is for validation purposes and should be left unchanged.